Inhibitors of Leishmania mexicana CRK3 cyclin-dependent kinase: Chemical library screen and antileishmanial activity

Antimicrobial Agents and Chemotherapy

Volumn 48, Issue 8, 2004, Pages 3033-3042

  Grant, Karen M ^a   Dunion, Morag H ^a   Yardley, Vanessa ^b   Skaltsounis, Alexios Leandros ^c   Marko, Doris ^d   Eisenbrand, Gerhard ^d   Croft, Simon L ^b   Meijer, Laurent ^e   Mottram, Jeremy C ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^c UNIVERSITY OF ATHENS   (Greece)

^d Rheinland Pfälzische Technische Universität Kaiserslautern Landau   (Germany)

^e STATION BIOLOGIQUE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILEISHMANIAL AGENT; CRK3 CYCLIN DEPENDENT KINASE INHIBITOR; CYCLIN DEPENDENT KINASE INHIBITOR; INDIRUBIN; PAULLONE; PROTEIN KINASE; PURINE DERIVATIVE; STAUROSPORINE; UNCLASSIFIED DRUG;

AMASTIGOTE; ANIMAL CELL; ANTIMICROBIAL ACTIVITY; ARTICLE; CELL CYCLE; CONTROLLED STUDY; DNA CONTENT; DOSE RESPONSE; DRUG MECHANISM; DRUG SCREENING; DRUG TARGETING; ENZYME INHIBITION; GENETIC MANIPULATION; IC 50; IN VITRO STUDY; LEISHMANIA DONOVANI; LEISHMANIA MEXICANA; MACROPHAGE; NONHUMAN; PHARMACOPHORE; PRIORITY JOURNAL;

ANIMALS; ANTIPROTOZOAL AGENTS; CDC2 PROTEIN KINASE; CELL CYCLE; CELLS, CULTURED; CYCLIN-DEPENDENT KINASES; DNA, PROTOZOAN; DRUG EVALUATION, PRECLINICAL; FLOW CYTOMETRY; FLUORESCENT DYES; GENE LIBRARY; HUMANS; IMMUNOBLOTTING; INDOLES; KARYOTYPING; LEISHMANIA MEXICANA; LEISHMANIASIS, CUTANEOUS; MACROPHAGES, PERITONEAL; MICE; PROTEIN KINASES; PROTOZOAN PROTEINS;

EID: 3342936476     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.48.8.3033-3042.2004     Document Type: Article

References (42)

1. Alvar, J., C. Cañavate, B. Gutiérrez-Solar, M. Jiménez, F. Laguna, R. López-Vélez, R. Molina, and J. Moreno. 1997. Leishmania and human immunodeficiency virus coinfection: the first 10 years. Clin. Microbiol. Rev. 10:298-319.
2. Arana, B., N. Rizzo, and A. Diaz. 2001. Chemotherapy of cutaneous leishmaniasis: a review. Med. Microbiol. Immunol. 190:93-95.
3. Barrett, M. P., J. C. Mottram, and G. H. Coombs. 1999. Recent advances in identifying and validating drug targets in trypanosomes and leishmanias. Trends Microbiol. 7:82-88.
4. Bates, P. A., and L. Tetley. 1993. Leishmania mexicana: induction of metacyclogenesis by cultivation of promastigotes at acidic pH. Exp. Parasitol. 76:412-423.
5. Blow, J. J., and T. A. Prokhorova. 1999. Saying a firm 'no' to DNA rereplication. Nat. Cell Biol. 1:E175-E177.
6. Borgne, A., A. C. Ostvold, S. Flament, and L. Meijer. 1999. Intra-M phase-promoting factor phosphorylation of cyclin B at the prophase/metaphase transition. J. Biol. Chem. 274:11977-11986.
7. Breitling, R., S. Klingner, N. Callewaert, R. Pietrucha, A. Geyer, G. Ehrlich, R. Hartung, A. Müller, R. Contreras, S. M. Beverley, and K. Alexandrov. 2002. Non-pathogenic trypanosomatid protozoa as a platform for protein research and production. Protein Express. Purif. 25:209-218.
8. Brizuela, L., G. Draetta, and D. Beach. 1989. Activation of human cdc2 protein as a histone h-1 kinase is associated with complex-formation with the p62 subunit. Proc. Natl. Acad. Sci. USA 86:4362-4366.
9. Bryceson, A. 2001. Current issues in the treatment of visceral leishmaniasis. Med. Microbiol. Immunol. 190:81-84.
10. Damiens, E., B. Baratte, D. Marie, G. Eisenbrand, and L. Meijer. 2001. Anti-mitotic properties of indirubin-3′-monoxime, a CDK/GSK-3 inhibitor: induction of endoreplication following prophase arrest. Oncogene 20:3786-3797.
11. Fischer, C., A. Voss, and J. Engel. 2001. Development status of miltefosine as first oral drug in visceral and cutaneous leishmaniasis. Med. Microbiol. Immunol. 190:85-87.
12. Fischer, L., J. Endicott, and L. Meijer. 2003. Cyclin-dependent kinase inhibitors, p. 235-248. In L. Meijer, A. Jézéquel, and M. Roberge (ed.), Cell cycle regulators as therapeutic targets. Progress in cell cycle research, vol. 5. Editions "Life in Progress," Station Biologique de Roscoff, Roscoff, France.
13. cks1. J. Biol. Chem. 273:10153-10159.
14. Gray, N. S., L. Wodicka, A. H. Thunnissen, T. C. Norman, S. J. Kwon, F. H. Espinoza, D. O. Morgan, G. Barnes, S. Leclerc, L. Meijer, S. H. Kim, D. J. Lockhart, and P. G. Schultz. 1998. Exploiting chemical libraries, structure, and genomics in the search for kinase inhibitors. Science 281:533-538.
15. Hammarton, T. C., J. Clark, F. Douglas, M. Boshart, and J. C. Mottram. 2003. Stage-specific differences in cell cycle control in Trypanosoma brucei revealed by RNA interference of a mitotic cyclin. J. Biol. Chem. 278:22877-22886.
16. Hassan, P., D. Fergusson, K. M. Grant, and J. C. Mottram. 2001. The CRK3 protein kinase is essential for cell cycle progression of Leishmania mexicana. Mol. Biochem. Parasitol. 113:189-198.
17. Havlícek, L., J. Hanus, J. Vesely, S. Leclerc, L. Meijer, G. Shaw, and M. Strnad. 1997. Cytokinin-derived cyclin-dependent kinase inhibitors: synthesis and cdc2 inhibitory activity of olomoucine and related compounds. J. Med. Chem. 40:408-412.
18. Hoessel, R., S. Leclerc, J. A. Endicott, M. E. M. Nobel, A. Lawrie, P. Tunnah, M. Leost, E. Damiens, D. Marie, D. Marko, E. Niederberger, W. C. Tang, G. Eisenbrand, and L. Meijer. 1999. Indirubin, the active constituent of a Chinese antileukaemia medicine, inhibits cyclin-dependent kinases. Nat. Cell Biol. 1:60-67.
19. Kitagawa, M., T. Okabe, H. Ogino, H. Matsumoto, I. Suzuki-Takahashi, T. Kokubo, H. Higashi, S. Saitoh, Y. Taya, H. Yasuda, Y. Ohba, S. Nishimura, N. Tanaka, and A. Okuyama. 1993. Butyrolactone I, a selective inhibitor of cdk2 and cdc2 kinase. Oncogene 8:2425-2432.
20. Knockaert, M., N. Gray, E. Damiens, Y.-T. Chang, P. Grellier, K. M. Grant, D. Fergusson, J. C. Mottram, M. Soete, K. Le Roch, C. Doerig, P. G. Schultz, and L. Meijer. 2000. Intracellular targets of cyclin-dependent kinase inhibitors: identification by affinity chromatography using immobilised inhibitors. Chem. Biol. 7:411-422.
21. Knockaert, M., P. Greengard, and L. Meijer. 2002. Pharmacological inhibitors of cyclin-dependent kinases. Trends Pharmacol. Sci. 23:417-425.
22. Knockaert, M., K. Wieking, S. Schmitt, M. Leost, K. M. Grant, J. C. Mottram, C. Kunick, and L. Meijer. 2002. Intracellular targets of paullones: Identification following affinity purification on immobilized inhibitor. J. Biol. Chem. 277:25493-25501.
23. Kunick, C., C. Schultz, T. Lemcke, D. W. Zaharevitz, R. Gussio, R. K. Jalluri, E. A. Sausville, M. Leost, and L. Meijer. 2000. 2-Substituted paullones: CDK1/cyclin B-inhibiting property and in vitro antiproliferative activity. Bioorg. Med. Chem. Lett. 10:567-569.
24. 1-phase and B-type cyclins exclude the DNA-replication factor Mcm4 from the nucleus. Nat. Cell Biol. 1:415-422.
25. Leclerc, S., M. Garnier, R. Hoessel, D. Marko, J. A. Bibb, G. L. Snyder, P. Greengard, J. Biernat, Y. Z. Wu, E. M. Mandelkow, G. Eisenbrand, and L. Meijer. 2001. Indirubins inhibit glycogen synthase kinase-3β and CDK5/P25, two protein kinases involved in abnormal tau phosphorylation in Alzheimer's disease: a property common to most cycline-dependent kinase inhibitors? J. Biol. Chem. 276:251-260.
26. Leost, M., C. Schultz, A. Link, Y. Z. Wu, J. Biernat, E. M. Mandelkow, J. A. Bibb, G. L. Snyder, P. Greengard, D. W. Zaharevitz, R. Gussio, A. M. Senderowicz, E. A. Sausville, C. Kunick, and L. Meijer. 2000. Paullones are potent inhibitors of glycogen synthase kinase-3β and cyclin-dependent kinase 5/p25. Eur. J. Biochem. 267:5983-5994.
27. Losiewicz, M. D., B. A. Carlson, G. Kaur, E. A. Sausville, and P. J. Worland. 1994. Potent inhibition of CDC2 kinase activity by the flavonoid L86-8275. Biochem. Biophys. Res. Commun. 201:589-595.
28. Marko, D., S. Schätzle, A. Friedel, A. Genzlinger, H. Zanld, L. Meijer, and G. Eisenbrand. 2001. Inhibition of cyclin-dependent kinase 1 (CDK1) by indirubin derivatives in human tumour cells. Br. J. Cancer 84:283-289.
29. Meijer, L., A. Borgne, O. Mulner, J. P. J. Chong, J. J. Blow, N. Inagaki, M. Inagaki, J. G. Delcros, and J. P. Moulinoux. 1997. Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2 and cdk5. Eur. J. Biochem. 243:527-536.
30. Meijer, L., and E. Raymond. 2003. Roscovitine and other purines as kinase inhibitors. From starfish oocytes to clinical trials. Acc. Chem. Res. 36:417-425.
31. Mettey, Y., M. Gompel, V. Thomas, M. Garnier, M. Leost, I. Ceballos-Picot, M. Noble, J. Endicott, J. M. Vierfond, and L. Meijer. 2003. Aloisines, a new family of CDK/GSK-3 inhibitors. SAR study, crystal structure in complex with CDK2, enzyme selectivity, and cellular effects. J. Med. Chem. 46:222-236.
32. Milligan, K. 1996. Cell cycle, growth and differentiation in Trypanosoma brucci and Leishmania species. Ph.D. thesis. University of Glasgow, Glasgow, United Kingdom.
33. Moreno, S., J. Hayles, and P. Nurse. 1989. Regulation of p34cdc2 protein kinase during mitosis. Cell 58:361-372.
34. suc1, associates with a stage-regulated histone H1 kinase. Biochem. J. 316:833-839.
35. Mottram, J. C., J. Kinnaird, B. R. Shiels, A. Tait, and J. D. Barry. 1993. A novel CDC2-related protein kinase from Leishmania mexicana, lmmCRK1, is post-translationally regulated during the life-cycle. J. Biol. Chem. 268:21044-21051.
36. Pan, Z.-Q., and J. Hurwitz. 1993. Reconstitution of cyclin-dependent cdc2 and cdk2 kinase activities in vitro. J. Biol. Chem. 268:20433-20442.
37. Pavletich, N. P. 1999. Mechanisms of cyclin-dependent kinase regulation: structures of Cdks, their cyclin activators, and Cip and INK4 inhibitors. J. Mol. Biol. 287:821-828.
38. Perez-Victoria, J. M., F. J. Perez-Victoria, A. Parodi-Talice, I. A. Jimenez, A. G. Ravelo, S. Castanys, and F. Gamarro. 2001. Alkyl-lysophospholipid resistance in multidrug-resistant Leishmania tropica and chemosensitization by a novel P-glycoprotein-like transporter modulator. Antimicrob. Agents Chem. 45:2468-2474.
39. Sundar, S. 2001. Treatment of visceral leishmaniasis. Med. Microbiol. Immunol. 190:89-92.
40. Wang, Y. X., K. Dimitrov, L. K. Garrity, S. Sazer, and S. M. Beverley. 1998. Stage-specific activity of the Leishmania major CRK3 kinase and functional rescue of a Schizosaccharomyces pombe cdc2 mutant. Mol. Biochem. Parasitol. 96:139-150.
41. Yang, Y., S. Zhao, and J. Song. 2004. Caspase-dependent apoptosis and -independent poly(ADP-ribose) polymerase cleavage induced by transforming growth factor beta1. Int. J. Biochem. Cell Biol. 36:223-234.
42. Zaharevitz, D. W., R. Gussio, M. Leost, A. M. Senderowicz, T. Lahusen, C. Kunick, L. Meijer, and E. A. Sausville. 1999. Discovery and initial characterization of the paullones, a novel class of small-molecule inhibitors of cyclin-dependent kinases. Cancer Res. 59:2566-2569.